Concepedia

Author

Anna Christoforidou

Democritus University of ThraceORCID

Also Known As

A. Christoforidou, A. V. Christoforidou, A.V. Christoforidou, Anna Christoforidou, Anna V Christoforidou, Anna V. Christoforidou

54

Publications

496

Citations

12

H-Index

48

Concepts

All Affiliations

Democritus University of ThraceNational and Kapodistrian University of AthensSt Savas HospitalLaiko General Hospital of AthensUniversity of Crete
AC

About

Anna Christoforidou is an author at Democritus University of Thrace specializing in medicine, hematology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

192

2

Health Sciences

4

4

122

3

Diagnostic Sciences

2

2

43

4

Cell Biology

1

1

16

5

Emergency Medicine

1

1

10

Anna Christoforidou

×

14

Publications

333

Citations

12

H-Index

YearCitations

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Eirini Katodritou, Evangelos Terpos, Argiris Symeonidis,

American Journal of Hematology

2014

67

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

Flora Zagouri, Efstathios Kastritis, Athanasios Zomas,

European Journal Of Haematology

2017

46

Expression of the Tpl2/Cot oncogene in human T-cell neoplasias.

Anna Christoforidou, Helen Α. Papadaki, Andrew N. Margioris,

Molecular Cancer

2004

44

Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes

Anna Christoforidou, Rima M. Saliba, Patricia Williams,

Biology of Blood and Marrow Transplantation

2007

29

Alendronate reduces serum TNF? and IL-1?, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis

Helen Α. Papadaki, Christos Tsatsanis, Anna Christoforidou,

Journal of Bone and Mineral Metabolism

2004

28

Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

Emmanouil Spanoudakis, Ioanna Bazdiara, Ιoannis Kotsianidis,

Annals of Hematology

2008

16

CD1d expression as a prognostic marker for chronic lymphocytic leukemia

Athanasios Anastasiadis, Ιoannis Kotsianidis, Vasileios Papadopoulos,

Leukemia & lymphoma/Leukemia and lymphoma

2013

16

Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group

Eirini Katodritou, Efstathios Kastritis, Moshe E. Gatt,

American Journal of Hematology

2020

16

Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy

Anna Christoforidou, Despina Pantelidou, Athanasios Anastasiadis,

Acta Haematologica

2008

14

Hyperhemolytic Syndrome complicating a Delayed Hemolytic Transfusion Reaction due to anti-P1 alloimmunization, in a pregnant woman with HbO-Arabβ-thalassemia

Zoe Bezirgiannidou, Anna Christoforidou, Eftychia Kontekaki,

Mediterranean Journal of Hematology and Infectious Diseases

2016

13

Page 1